157 Church St, 19th Floor

New Haven, 06510

Do You Qualify for Spravato in New Haven? Eligibility, the REMS Program, and the Two Approved Uses of Esketamine

If you’re exploring Spravato treatment in New Haven, a common first question is: Do I meet the requirements? The answer depends partly on which of the medication’s two FDA-approved uses is being considered, and on a clinician’s assessment of your diagnosis, treatment history, safety, and care needs.

At Light-tunnel Behavioral Health Services Inc. in New Haven, Dr. Omolola Aragbada, PMHNP-BC, is one of the practice’s psychiatric providers. A psychiatric evaluation can help you understand your depression treatment options and what questions to ask about esketamine. Eligibility is not something you can determine from a checklist alone, but knowing the basics can make the conversation easier.

First, what is Spravato approved to treat?

Spravato is the brand name for esketamine nasal spray, a prescription medication administered under supervision in a certified healthcare setting. For adults, the FDA has approved it for two distinct situations:

  1. Treatment-resistant depression (TRD): It may be used on its own or alongside an oral antidepressant.
  2. Depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior: It must be used with an oral antidepressant.

These are different indications, not two names for the same eligibility pathway. Neither means that a person is guaranteed to benefit, and a prescriber must evaluate whether treatment is appropriate and safe.

Two approved uses, side by side

Treatment-resistant depressionMDD with acute suicidal ideation or behavior
Who is it for?Adults with TRD: depression that has not responded adequately to at least two oral antidepressant treatments.Adults with MDD who have acute suicidal ideation or behavior and depressive symptoms.
Must you have tried two oral antidepressants?Yes, as part of the TRD treatment history. A clinician reviews which treatments you tried and whether each trial was adequate.Not as a specific FDA eligibility requirement for this indication. The prescriber still assesses your full history and needs.
Must you take an oral antidepressant with Spravato?Not necessarily. The FDA-approved TRD indication allows Spravato as monotherapy or with an oral antidepressant.Yes. It is approved for use with an oral antidepressant.
What does the setting require?Administration through the Spravato REMS program, with observation after each dose.The same REMS safeguards. Acute suicide risk may also call for emergency or inpatient care.
Important limitationA past treatment history alone does not establish that Spravato is the right choice.It has not been shown to prevent suicide or to reduce suicidal thoughts or behavior. It does not replace emergency care or hospitalization when needed.

The 2025 FDA prescribing information includes both indications and their distinct antidepressant requirements. Read the FDA label.

A White adult patient discusses treatment history with a Black psychiatric clinician

What does “treatment-resistant depression” mean in practice?

The term can sound as if depression is impossible to treat. It doesn’t mean that. In this context, it generally means that an adult’s depression has not improved enough after trying at least two oral antidepressants. Your psychiatric provider will consider the specific medications, doses, length of each trial, how consistently they were taken, and what response or side effects you experienced.

A medication trial is a little like testing whether a key fits a difficult lock: the key needs to be the right one, and it needs to be tried properly before you know whether it works. That review is not a judgment about you or your effort. Depression is complex, and an inadequate response can happen even when you’ve followed a treatment plan.

Randomized controlled trials of esketamine for TRD, including TRANSFORM-1 and TRANSFORM-2-studied esketamine alongside a newly started oral antidepressant; their findings support the evidence base for combination treatment, but they do not predict an individual person’s outcome (Fedgchin et al., 2019; Popova et al., 2019). The FDA’s later approval of Spravato as a monotherapy option for adults with TRD reflects additional evidence and a labeling change; it does not mean every person who meets the treatment-history definition should stop or change other medication without clinical guidance.

A separate randomized-withdrawal trial, SUSTAIN-1, found that among participants who first achieved stable remission or response with esketamine plus an oral antidepressant, continuing esketamine delayed relapse compared with switching to placebo nasal spray while continuing the antidepressant. Because participants had already responded or remitted before randomization, the result informs maintenance decisions for that group; it is not a way to determine whether you initially qualify (Daly et al., 2019).

What if the concern is acute suicidal thoughts?

This FDA-approved use applies to adults with MDD and acute suicidal ideation or behavior. It does not require the specific two-prior-antidepressant history associated with the TRD indication. The clinician must still evaluate the person’s current symptoms, diagnosis, immediate safety, treatment history, and appropriate level of care.

In the ASPIRE I and ASPIRE II randomized trials, participants received esketamine or placebo nasal spray alongside comprehensive standard care, including hospitalization and oral antidepressant treatment. Esketamine improved depressive-symptom scores more than placebo at the measured early time point; however, the studies did not demonstrate a statistically significant between-group advantage in reducing the severity of suicidality (ASPIRE I: Fu et al., 2020; ASPIRE II: Ionescu et al., 2021). This distinction matters: improvement in depression symptoms is not proof that suicide has been prevented.

If you or someone close to you may be in immediate danger, do not wait for an outpatient Spravato appointment. Seek urgent help using the crisis resources at the end of this article.

What does the REMS program mean for you?

Spravato is available only through a restricted safety program called REMS (Risk Evaluation and Mitigation Strategy). It cannot simply be picked up at a retail pharmacy and used at home. It must be administered in a certified healthcare setting, under direct observation, and you must be monitored for at least two hours after each administration. The observation period helps staff monitor for risks that can include sedation, dissociation, and respiratory depression.

Before arranging an in-person appointment in New Haven, ask the practice whether it is currently REMS-certified to provide Spravato, what an evaluation involves, and what insurance authorization or costs may apply. A clinic’s general ability to provide psychiatric care does not by itself mean it is certified to administer this medication.

An adult Hispanic patient has a calm check-in with a Black clinical staff member in a supervised outpatient setting

Questions to ask at a New Haven evaluation

Consider bringing a medication list and notes about what you have tried. You might ask:

  • Which Spravato indication, if any, could apply to my situation?
  • Do my past antidepressant trials count as adequate trials for the TRD indication?
  • If I take Spravato, would I also need an oral antidepressant?
  • Is the treatment setting REMS-certified, and what monitoring and transportation arrangements are needed?
  • What other depression treatment options should I compare, including therapy or medication management for depression?
  • What would my estimated costs be, including if I am self-pay?

At Light-tunnel Behavioral Health Services Inc. in New Haven, self-pay clients can ask about a psychiatric evaluation, medication management, therapy, and which services may fit their needs. Ask for a clear estimate of evaluation, treatment, and follow-up costs before proceeding; insurance coverage and out-of-pocket expenses vary. You can review the practice’s services, contact the team, or request an appointment. Dr. Omolola Aragbada, PMHNP-BC, is one of the psychiatric providers who can help you discuss care options.

Medical disclaimer and crisis support

This article is for educational purposes only and is not a diagnosis or a substitute for individualized medical advice. Spravato has important risks, eligibility requirements, and monitoring safeguards. Only a qualified healthcare professional can determine whether it may be appropriate for you.

If you are thinking about suicide or are worried about someone’s immediate safety, call or text 988 in the United States for the Suicide & Crisis Lifeline. If there is immediate danger or a medical emergency, call 911 or go to the nearest emergency department. Do not wait for a routine appointment.

References

  • U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray: Prescribing Information. 2025.
  • Fedgchin M, Trivedi M, Daly EJ, et al. “Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).” International Journal of Neuropsychopharmacology. 2019. PubMed
  • Popova V, Daly EJ, Trivedi M, et al. “Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (TRANSFORM-2).” American Journal of Psychiatry. 2019. PubMed
  • Daly EJ, Trivedi MH, Janik A, et al. “Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial (SUSTAIN-1).” JAMA Psychiatry. 2019. PubMed
  • Fu DJ, Ionescu DF, Li X, et al. “Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).” Journal of Clinical Psychiatry. 2020. PubMed
  • Ionescu DF, Fu DJ, Qiu X, et al. “Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).” International Journal of Neuropsychopharmacology. 2021. PubMed

Continue the Series

For a related discussion of ongoing care, read “Do You Really Need Lifelong Spravato? Here’s the Truth About Esketamine Maintenance”.